Abstract CT082: Impact of tumor mutation burden on the efficacy of first-line nivolumab in stage iv or recurrent non-small cell lung cancer: An exploratory analysis of CheckMate 026
Year: 2017
Type: conference-abstract
Source: Cancer Research
Institutions: Centre Hospitalier Universitaire Vaudois, Moffitt Cancer Center, Memorial Sloan Kettering Cancer Center, Florida Hospital Cancer Institute, German Center for Lung Research, Bristol-Myers Squibb (United States), The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, The Ohio State University
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W2741036937